Enlivex Therapeutics Ltd. - ENLV

About Gravity Analytica
Recent News
- 04.30.2026 - Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
- 04.28.2026 - Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
- 04.23.2026 - Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
- 04.21.2026 - Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
- 04.08.2026 - Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares
Recent Filings
- 05.01.2026 - 424B3 Prospectus [Rule 424(b)(3)]
- 04.30.2026 - EFFECT Notice of Effectiveness
- 04.21.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
- 04.21.2026 - EX-99.1 EX-99.1
- 04.21.2026 - F-3 Registration statement by foreign private issuers
- 04.08.2026 - EX-99.1 EX-99.1
- 04.08.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
- 03.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
- 03.26.2026 - EX-99.1 EX-99.1
- 03.25.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]